
    
      Primary Purpose of this study is to compare the pharmacokinetic (PK) of Abatacept
      (BMS-188667) manufactured at Lonza relative to Abatacept (BMS-188667) manufactured at Devens,
      MA facility following a single intravenous infusion of 750 mg in healthy subjects
    
  